…Novartis, may be one legal step away from upending the Indian supply chain by forcing the Indian government to recognize a patent for a cancer treatment heralded as a breakthrough for people with a deadly form of leukemia…The case, involving the drug Gleevec, is before the Indian Supreme Court, which is preparing to hear final arguments this month. It represents a high-stakes showdown between defenders of intellectual property rights, who say the generic knockoffs stifle innovation by drug makers, and Indian drug companies and international aid groups, who warn that a ruling in favor of Novartis could dry up the global supply of inexpensive medicines to treat AIDS, cancer and other diseases...The Indian government denied the patent for Gleevec, as it has for many other drugs made by many Western drug makers. Novartis sued, and the case has been winding through the Indian legal system for six years…[also refers to Roche, Gilead Sciences]